Evidence map›Paper›PMID 32518601›Full record

ArticleRevue francophone des laboratoires : RFL2009

[Use of lactic acid bacteria as mucosal vaccines].

Luis G Bermúdez-Humarán, Philippe Langella

Open access · greenAbstract readEnglish Abstract
In one paragraph

Article in Revue francophone des laboratoires : RFL, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 75% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Luis G Bermúdez-HumaránINRA 0910 - Unité d'écologie et de physiologie du système digestif, 78352 Jouy-en-Josas.
Philippe LangellaINRA 0910 - Unité d'écologie et de physiologie du système digestif, 78352 Jouy-en-Josas.
Virologie et Immunologie Moléculaires · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Today, sufficient consistent data are available to reinforce the interest of the use of Lactic Acic Bacteria (LAB), particularly lactococci and lactobacilli strains, to develop novel mucosal vaccination strategies. LAB are Gram positive bacteria exploited since the highest Antiquity by humans to produce fermented foods. They are thus good candidates to develop novel oral vectors and constitute attractive alternatives to vaccinal strategies based on attenuated pathogens which could induce healthy risks. Here, we summarized the most recent researches performed on the use of LAB as live vaccine delivery vectors.

Indexed as

antigenesLactic acid bacteriaLactobacillus spp.Lactococcus lactislive vaccinesmucosal vectors

Identifiers

PMID32518601
PMCPMC7270964
OpenAlexW2159652744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.